A new white paper from Thermo Fisher Scientific outlines how integrating advanced technologies can speed up early-stage biologic development. By leveraging artificial intelligence and machine learning (AI/ML), enhanced cell line development, and intensified manufacturing processes, developers can reduce the time needed to reach Investigational New Drug (IND) applications and first-in-human trials.
The approach aims to minimize trial-and-error phases common in biologics development, enabling more efficient progression through critical milestones. The white paper is available for free download and provides insights into how these technologies can optimize drug development workflows.
**Why this matters**
Early-stage biologics face significant time pressures to move from discovery to clinical testing. Implementing technology-driven strategies can help overcome development bottlenecks, potentially accelerating the availability of new therapies. This can improve competitiveness for biotech companies and ultimately benefit patients by bringing treatments to market sooner.
Source: NewsData